Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

969 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Involvement of vasoactive intestinal peptide on insulin-like growth factor I-induced proliferation of rat pituitary lactotropes in primary culture: evidence for an autocrine and/or paracrine regulatory system.
Fernández M, Sánchez-Franco F, Palacios N, Sánchez I, Villuendas G, Cacicedo L. Fernández M, et al. Among authors: sanchez i, sanchez franco f. Neuroendocrinology. 2003 May;77(5):341-52. doi: 10.1159/000070900. Neuroendocrinology. 2003. PMID: 12806180
IGF-I and vasoactive intestinal peptide (VIP) regulate cAMP-response element-binding protein (CREB)-dependent transcription via the mitogen-activated protein kinase (MAPK) pathway in pituitary cells: requirement of Rap1.
Fernández M, Sánchez-Franco F, Palacios N, Sánchez I, Cacicedo L. Fernández M, et al. Among authors: sanchez i, sanchez franco f. J Mol Endocrinol. 2005 Jun;34(3):699-712. doi: 10.1677/jme.1.01703. J Mol Endocrinol. 2005. PMID: 15956341
Dobesilate is an angiogenesis inhibitor.
Cuevas P, Sanchez I, Lozano RM, Gimenez-Gallego G. Cuevas P, et al. Among authors: sanchez i. Eur J Med Res. 2005 Sep 12;10(9):369-72. Eur J Med Res. 2005. PMID: 16183547 Free article.
Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial.
Davies C, Pan H, Godwin J, Gray R, Arriagada R, Raina V, Abraham M, Medeiros Alencar VH, Badran A, Bonfill X, Bradbury J, Clarke M, Collins R, Davis SR, Delmestri A, Forbes JF, Haddad P, Hou MF, Inbar M, Khaled H, Kielanowska J, Kwan WH, Mathew BS, Mittra I, Müller B, Nicolucci A, Peralta O, Pernas F, Petruzelka L, Pienkowski T, Radhika R, Rajan B, Rubach MT, Tort S, Urrútia G, Valentini M, Wang Y, Peto R; Adjuvant Tamoxifen: Longer Against Shorter (ATLAS) Collaborative Group. Davies C, et al. Lancet. 2013 Mar 9;381(9869):805-16. doi: 10.1016/S0140-6736(12)61963-1. Lancet. 2013. PMID: 23219286 Free PMC article. Clinical Trial.
969 results